Both organisations are focused on driving collaborative innovation to combat the global challenge of infectious disease – saving and improving the lives of millions in communities across the world.
BactiVac is a global bacterial vaccinology network bringing together members based in academic, industry and policy sectors to accelerate the development of vaccines against bacterial infections relevant to low and middle-income countries (LMICs).
iiCON is a world-leading collaborative infectious disease R&D programme. It brings together industry, academia, and the NHS in a £174 million programme to accelerate the discovery, development and deployment of new antimicrobial treatments and products. Led by LSTM, its partners are Unilever, Evotec, Liverpool University Hospitals Foundation Trust, The University of Liverpool, and Infex Therapeutics.
Professor Janet Hemingway, Director of iiCON, said: “We’re delighted to be formally strengthening our relationship with BactiVac through this MOU. Our collaborative effort will leverage complementary strengths, enhancing capability and capacity as we work together to accelerate innovation to address the global challenge of infectious disease.”
Prof. Cal MacLennan, Director of BactiVac, said: “Working collaboratively with consortia such as iiCON will be key to delivering our aim of accelerating the development of vaccines against bacterial pathogens. BactiVac is delighted to have taken this first step in establishing a partner relationship with iiCON. We very much look forward to identifying ways in which our respective networks can synergise together to combat the global scourge of infectious diseases and save lives.”
To find out more about iiCON, visit: www.infectioninnovation.com